Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Plus Apatinib as Adjuvant Therapy in High-Risk HCC
NCT06454578Phase 2Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in hepatocellular carcinoma (HCC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Recurrence-Free Survival Rate at 24 months. Started Jul 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06454578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06454578.